VTCN1 Antikörper (AA 50-100)
-
- Target Alle VTCN1 Antikörper anzeigen
- VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))
-
Bindungsspezifität
- AA 50-100
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser VTCN1 Antikörper ist unkonjugiert
-
Applikation
- ELISA, Flow Cytometry (FACS), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))
- Kreuzreaktivität
- Human
- Homologie
- Mouse,Rat,Dog
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from Rat B7H4
- Isotyp
- IgG
-
-
- Applikationshinweise
-
ELISA 1:500-1000
FCM 1:20-100
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- Haltbarkeit
- 12 months
-
-
Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis." in: Tumour biology, (2014) (PubMed).
: "
-
Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis." in: Tumour biology, (2014) (PubMed).
-
- Target
- VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))
- Andere Bezeichnung
- B7H4 (VTCN1 Produkte)
- Synonyme
- B7h4 antikoerper, B7s1 antikoerper, B7x antikoerper, BC032925 antikoerper, B7-H4 antikoerper, B7H4 antikoerper, B7S1 antikoerper, B7X antikoerper, B7h.5 antikoerper, PRO1291 antikoerper, VCTN1 antikoerper, RGD1311204 antikoerper, V set domain containing T cell activation inhibitor 1 L homeolog antikoerper, V-set domain containing T cell activation inhibitor 1 antikoerper, V-set domain containing T-cell activation inhibitor 1 antikoerper, V set domain containing T cell activation inhibitor 1 antikoerper, vtcn1.L antikoerper, VTCN1 antikoerper, vtcn1 antikoerper, Vtcn1 antikoerper
- Hintergrund
-
Synonyms: RGD1311204, V-set domain-containing T-cell activation inhibitor 1, Vtcn1
Background: Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation (By similarity).
- Gen-ID
- 295322
- UniProt
- Q501W4
-